Distinguished in Lung Adenocarcinoma

Yasushi O. Goto

Tokyo, JP 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Lung Adenocarcinoma
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Yasushi Goto practices in Tokyo, Japan. Goto is rated as a Distinguished expert by MediFind in the treatment of Lung Adenocarcinoma. Their top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Thymic Epithelial Tumor, Tissue Biopsy, and Endoscopy.

Their clinical research consists of co-authoring 235 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 15 articles in the study of Lung Adenocarcinoma.

Locations

Tokyo, Japan
Other Locations
Chuo, Japan
Kashiwa, Japan
Minato, 1050003, Japan
Kobe, Japan
Hamamatsu, 4300929, Japan
Toyoake, Japan
Chuo, Japan
Tsukuba, 3058575, Japan
Hongo, Japan
Suita, Japan
Yaizu, 4210212, Japan
Nagoya, 4648602, Japan
Career Path Promotion Unit For Young Life Scientists, Yoshida Konoe Cho, Kyoto, Japan
Shinjuku, 1628655, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2

235 Total Publications

Erratum to 'Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis': [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399].
Erratum to 'Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis': [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 08, 2026

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Goto's expertise for a condition
ConditionClose
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile